Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You gonna make it ???
Shortages: Elites future looks bright
Perfect storm is a brewing
FDA shortage link for Adderall:
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet&st=c&tab=tabs-1
FDA shortage link for Vyvance
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Lisdexamfetamine%20Dimesylate%20Capsule&st=c
FDA shortage link for Concerta
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release&st=c
FDA shortage link for Naltrexone
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Naltrexone%20Hydrochloride%20Tablet&st=c
FDA shortage link for Methotrexate
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Methotrexate%20Sodium%20Tablet&st=c
Bullish
BULLISH
X. $0.0269
X. $0.03
X. $0.04
X. $0.05
X. $0.06
X. $0.07
X. $0.08
X. $0.09
X. $0.10
X. $0.11
X. $0.12
X. $0.13
X. $0.14
X. $0.15
X. $0.16
X. $0.17
X. $0.18
X. $0.19
_. $0.20
_. $0.21
NEWS IMMINENT:
X 1. Cash Flow Positive - 5 years
X 2. Purchase building housing their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
X 3. Adderall IR $335 Million IMS market Approved and Launched
X 4. Adderall XR $1.56 Billion IMS market Approved and Launched
X 5. Double digit quarterly revenues in millions
X 6. Create in house marketing and distribution: Kirko Kirkov, Doug Plassche and their teams
X 7. Prasco/Burel Adderall agreement - January 1st 2024
X 8. First shipment Adderall XR to Prasco Dec 2023
X 9. DEA increases manufacturing quotas for Adderall & Vyvance
X 10. Generic OxyContin - FIRST TO FILE Aug 17, 2023 $720 Million
X 11. Generic Vyvanse - $5.1 BILLION - FDA submission Dec 2023
X 12. FDA Acceptance of Generic OxyContin Sept 2023
X 13. Lease additional manufacturing space and storage vault for new Needle Mover ANDAs - Jan 2024
__14. Dopamine Agonist (probably Requip XL or Mirapex ER). $12 Million
X 15. Vigabatrin Approval $233 Million
X 16. Pyros Vigabatrin -settle VigPoder trade mark challenge then LAUNCH
X 17. Generic Methotrexate Approval- Antimetabolite $42 Million
X 18. $50+ million in yearly revenues
X 19. Lowest PE ratio for OTC Healthcare sector
X 20. Become the ONLY company showing rapid growth on the OTC while being profitable
__21. Generate revenues over $20 million/quarter
X.22. Receive Analyst Coverage - Upgrade to Market Outperform - Zacks Investment Research
__23. Double output of manufacturing and packaging facilities
__24. Generic OxyContin Approval FIRST TO FILE Aug 17, 2023 $720 Million
__25. Prevail over Purdue in Generic OxyContin infringement suit - 6 month stay
__26. Launch Tylenol with codeine $45 Million
__27. Launch generic Norco - hydrocodone acetaminophen IMS $477 Million
__28. Launch generic Percocet - oxycodone acetaminophen IMS $500 Million
__29. Launch generic Dolophine - methadone HCL tablets IMS $30 Million
__30. European distribution - Dexcel partnership approval by Israeli Health
__31. Full ownership of Adderall IR $ 335 Million
__32. Full ownership of Adderall XR $ 1.56 Billion
__33. Generic Concerta- $1.2 BILLION FDA submission
__34. $100 million in yearly revenue
__35. Generic Vyvanse Approval and Launch
__36. $200 million in yearly revenue
__37. Deep pocket partner for SequestOx
__38. Patented Unique ADF (w/o naltrexone) drug C in SequestOx trial
__39. Mikah ANDA(s)
__40. Undisclosed ANDAs/NDAs
__41. Generic Concerta Approval and Launch
__42. DollarLand PPS
__43. Big Pharma bid
__44. UpList to the NASDAQ Exchange
__45. ELTP Elite Pharmaceutical Buyout - 2 1/2 years or less from Feb 2024
__46. Vegas Baby !!!!!!!
BULLISH
Im adding now before we go into the 20s
LOCKED $$ LOADED
ELTP Catalyst
For those keeping score.
X 1. Cash Flow Positive - 5 years
X 2. Purchase building housing their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
X 3. Adderall IR $335 Million IMS market Approved and Launched
X 4. Adderall XR $1.56 Billion IMS market Approved and Launched
X 5. Double digit quarterly revenues in millions
X 6. Create in house marketing and distribution: Kirko Kirkov, Doug Plassche and their teams
X 7. Prasco/Burel Adderall agreement - January 1st 2024
X 8. First shipment Adderall XR to Prasco Dec 2023
X 9. DEA increases manufacturing quotas for Adderall & Vyvance
X 10. Generic OxyContin - FIRST TO FILE Aug 17, 2023 $720 Million
X 11. Generic Vyvanse - $5.1 BILLION - FDA submission Dec 2023
X 12. FDA Acceptance of Generic OxyContin Sept 2023
X 13. Lease additional manufacturing space and storage vault for new Needle Mover ANDAs - Jan 2024
__14. Dopamine Agonist (probably Requip XL or Mirapex ER). $12 Million
X 15. Vigabatrin Approval $233 Million
X 16. Pyros Vigabatrin -settle VigPoder trade mark challenge then LAUNCH
X 17. Generic Methotrexate Approval- Antimetabolite $42 Million
X 18. $50+ million in yearly revenues
X 19. Lowest PE ratio for OTC Healthcare sector
X 20. Become the ONLY company showing rapid growth on the OTC while being profitable
__21. Generate revenues over $20 million/quarter
X.22. Receive Analyst Coverage - Upgrade to Market Outperform - Zacks Investment Research
__23. Double output of manufacturing and packaging facilities
__24. Generic OxyContin Approval FIRST TO FILE Aug 17, 2023 $720 Million
__25. Prevail over Purdue in Generic OxyContin infringement suit - 6 month stay
__26. Launch Tylenol with codeine $45 Million
__27. Launch generic Norco - hydrocodone acetaminophen IMS $477 Million
__28. Launch generic Percocet - oxycodone acetaminophen IMS $500 Million
__29. Launch generic Dolophine - methadone HCL tablets IMS $30 Million
__30. European distribution - Dexcel partnership approval by Israeli Health
__31. Full ownership of Adderall IR $ 335 Million
__32. Full ownership of Adderall XR $ 1.56 Billion
__33. Generic Concerta- $1.2 BILLION FDA submission
__34. $100 million in yearly revenue
__35. Generic Vyvanse Approval and Launch
__36. $200 million in yearly revenue
__37. Deep pocket partner for SequestOx
__38. Patented Unique ADF (w/o naltrexone) drug C in SequestOx trial
__39. Mikah ANDA(s)
__40. Undisclosed ANDAs/NDAs
__41. Generic Concerta Approval and Launch
__42. DollarLand PPS
__43. Big Pharma bid
__44. UpList to the NASDAQ Exchange
__45. ELTP Elite Pharmaceutical Buyout - 2 1/2 years or less from Feb 2024
__46. Vegas Baby !!!!!!!
Bullish
There’s only a few places that don’t have internet.
It’s about to get Real !!!!!!!!!
It was after you sold all your shares at 15
If he moved to England he may have a new IP address and can hAVE A NEW id
Who would have made a better partner for the Adderall's ?
Anyone else, I would doubt they would ever sell them back to Elite.
The Adderall's will come home to Elite before THE BUYOUT in 20 months or so.
X. $0.0269
X. $0.03
X. $0.04
X. $0.05
X. $0.06
X. $0.07
X. $0.08
X. $0.09
X. $0.10
X. $0.11
X. $0.12
X. $0.13
X. $0.14
X. $0.15
X. $0.16
X. $0.17
X. $0.18
X. $0.19
_. $0.20
_. $0.21
News Imminent:
ELTP Catalyst
X 1. Cash Flow Positive - 5 years
X 2. Purchase building housing their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
X 3. Adderall IR $335 Million IMS market Approved and Launched
X 4. Adderall XR $1.56 Billion IMS market Approved and Launched
X 5. Double digit quarterly revenues in millions
X 6. Create in house marketing and distribution: Kirko Kirkov, Doug Plassche and their teams
X 7. Prasco/Burel Adderall agreement - January 1st 2024
X 8. First shipment Adderall XR to Prasco Dec 2023
X 9. DEA increases manufacturing quotas for Adderall & Vyvance
X 10. Generic OxyContin - FIRST TO FILE Aug 17, 2023 $720 Million
X 11. Generic Vyvanse - $5.1 BILLION - FDA submission Dec 2023
X 12. FDA Acceptance of Generic OxyContin Sept 2023
X 13. Lease additional manufacturing space and storage vault for new Needle Mover ANDAs - Jan 2024
__14. Dopamine Agonist (probably Requip XL or Mirapex ER). $12 Million
X 15. Vigabatrin Approval $233 Million
X 16. Pyros Vigabatrin -settle VigPoder trade mark challenge then LAUNCH
X 17. Generic Methotrexate Approval- Antimetabolite $42 Million
X 18. $50+ million in yearly revenues
X 19. Lowest PE ratio for OTC Healthcare sector
X 20. Become the ONLY company showing rapid growth on the OTC while being profitable
__21. Generate revenues over $20 million/quarter
X.22. Receive Analyst Coverage - Upgrade to Market Outperform - Zacks Investment Research
__23. Double output of manufacturing and packaging facilities
__24. Generic OxyContin Approval FIRST TO FILE Aug 17, 2023 $720 Million
__25. Prevail over Purdue in Generic OxyContin infringement suit - 6 month stay
__26. Launch Tylenol with codeine $45 Million
__27. Launch generic Norco - hydrocodone acetaminophen IMS $477 Million
__28. Launch generic Percocet - oxycodone acetaminophen IMS $500 Million
__29. Launch generic Dolophine - methadone HCL tablets IMS $30 Million
__30. European distribution - Dexcel partnership approval by Israeli Health
__31. Full ownership of Adderall IR $ 335 Million
__32. Full ownership of Adderall XR $ 1.56 Billion
__33. Generic Concerta- $1.2 BILLION FDA submission
__34. $100 million in yearly revenue
__35. Generic Vyvanse Approval and Launch
__36. $200 million in yearly revenue
__37. Deep pocket partner for SequestOx
__38. Patented Unique ADF (w/o naltrexone) drug C in SequestOx trial
__39. Mikah ANDA(s)
__40. Undisclosed ANDAs/NDAs
__41. Generic Concerta Approval and Launch
__42. DollarLand PPS
__43. Big Pharma bid
__44. UpList to the NASDAQ Exchange
__45. ELTP Elite Pharmaceutical Buyout - 2 1/2 years or less from Feb 2024
__46. Vegas Baby !!!!!!!
Bullish
No selling on this end. Dont want to lose any $$
BuyOut Bound
Im toppin' off over the next 4 weeks.
Huge Quarter coming up.
ELTP
You will have to buy back in the 20s
Its about to get real !!!!!!!!!!!!!!!!!!!!! AUg 14-15
dont miss out $20 million quarter
I🐝
Near 52 week high
What is the 52 wk ROI ??
Thx in advance
👁️ eye
What if it dont go down ?
Pay lot more to buy it back ??
How many new ANDAs do we have filed with the FDA ??
Whats the market value for Elites VyVance ??
whats 5% - 10% of that ???
The BuyOut price is going UP !!!!!!!!!!!!!!!!
It will before CC in a few weeks, if not sooner.
Could be as soon as today.
The 19's are going
How much is the IMS market value of Elite upcoming Vyvance approval ??
ELTP
Whats the PE ratio ??
Thx in advance
And Tuesday .
ELTP
ELTP Catalyst
For those keeping score.
X 1. Cash Flow Positive - 5 years
X 2. Purchase building housing their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
X 3. Adderall IR $335 Million IMS market Approved and Launched
X 4. Adderall XR $1.56 Billion IMS market Approved and Launched
X 5. Double digit quarterly revenues in millions
X 6. Create in house marketing and distribution: Kirko Kirkov, Doug Plassche and their teams
X 7. Prasco/Burel Adderall agreement - January 1st 2024
X 8. First shipment Adderall XR to Prasco Dec 2023
X 9. DEA increases manufacturing quotas for Adderall & Vyvance
X 10. Generic OxyContin - FIRST TO FILE Aug 17, 2023 $720 Million
X 11. Generic Vyvanse - $5.1 BILLION - FDA submission Dec 2023
X 12. FDA Acceptance of Generic OxyContin Sept 2023
X 13. Lease additional manufacturing space and storage vault for new Needle Mover ANDAs - Jan 2024
__14. Dopamine Agonist (probably Requip XL or Mirapex ER). $12 Million
X 15. Vigabatrin Approval $233 Million
X 16. Pyros Vigabatrin -settle VigPoder trade mark challenge then LAUNCH
X 17. Generic Methotrexate Approval- Antimetabolite $42 Million
X 18. $50+ million in yearly revenues
X 19. Lowest PE ratio for OTC Healthcare sector
X 20. Become the ONLY company showing rapid growth on the OTC while being profitable
__21. Generate revenues over $20 million/quarter
X.22. Receive Analyst Coverage - Upgrade to Market Outperform - Zacks Investment Research
__23. Double output of manufacturing and packaging facilities
__24. Generic OxyContin Approval FIRST TO FILE Aug 17, 2023 $720 Million
__25. Prevail over Purdue in Generic OxyContin infringement suit - 6 month stay
__26. Launch Tylenol with codeine $45 Million
__27. Launch generic Norco - hydrocodone acetaminophen IMS $477 Million
__28. Launch generic Percocet - oxycodone acetaminophen IMS $500 Million
__29. Launch generic Dolophine - methadone HCL tablets IMS $30 Million
__30. European distribution - Dexcel partnership approval by Israeli Health
__31. Full ownership of Adderall IR $ 335 Million
__32. Full ownership of Adderall XR $ 1.56 Billion
__33. Generic Concerta- $1.2 BILLION FDA submission
__34. $100 million in yearly revenue
__35. Generic Vyvanse Approval and Launch
__36. $200 million in yearly revenue
__37. Deep pocket partner for SequestOx
__38. Patented Unique ADF (w/o naltrexone) drug C in SequestOx trial
__39. Mikah ANDA(s)
__40. Undisclosed ANDAs/NDAs
__41. Generic Concerta Approval and Launch
__42. DollarLand PPS
__43. Big Pharma bid
__44. UpList to the NASDAQ Exchange
__45. ELTP Elite Pharmaceutical Buyout - 2 1/2 years or less from Feb 2024
__46. Vegas Baby !!!!!!!
Bullish
GREEN ALL WEEK !!!!!!!!!!!!!!!!!!!!
My 9 accounts are swelling !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
Need a PE ratio update.
Thx in advance
Good fortune for me. Gives me time to sell some realistate.
Low prices will be gone Aug 14 or there abouts.
The Accumulation continues.
ELTP
Teens will be gone tomorrow
ELTP
Im always looking for ways to increase my position.
I put a vacant lot up for sale $$$$$$$$$$$$$
Must be back on the ask again.
Buy the bid & skip your BS
HAMMERTIME !!!!!!!!
Shortages:
FDA shortage link .
Norco
for Adderall:
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet&st=c&tab=tabs-1
FDA shortage link for Vyvance
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Lisdexamfetamine%20Dimesylate%20Capsule&st=c
FDA shortage link for Concerta
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release&st=c
FDA shortage link for Naltrexone
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Naltrexone%20Hydrochloride%20Tablet&st=c
FDA shortage link for Methotrexate
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Methotrexate%20Sodium%20Tablet&st=c